{"id":"W2961471425","doi":"10.1016/j.clml.2019.07.004","title":"Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Cilag; Janssen Pharmaceuticals; TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Sunesis; Astellas Pharma; Exelixis; Sun Pharma; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; AbbVie; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; Janssen Research and Development; MorphoSys; Pfizer; Biogen; Celgene; AstraZeneca; Amgen; Alexion Pharmaceuticals; Roche; GlaxoSmithKline","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001785766,0.0009673241,0.003235992,0.0005680854,0.0001395875,0.00009309498,0.0009041405,0.0007715977,0.0002671167],"category_scores_gemma":[0.001289811,0.0007067063,0.0006935218,0.00123547,0.001326374,0.0005980425,0.0005496891,0.0006876148,0.0004208386],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1491038,"about_ca_system_score_gemma":0.07385837,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005086615,"about_ca_topic_score_gemma":0.00009201391,"domain_scores_codex":[0.9912712,0.0005103271,0.002919374,0.001678686,0.001988981,0.001631425],"domain_scores_gemma":[0.9923714,0.002880226,0.0009648674,0.002286646,0.0008951994,0.0006016199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002678945,0.0003489622,0.835071,0.0006702816,0.001071767,0.0002662037,0.0001972976,0.0001922854,0.00009738119,0.00005966912,0.000175762,0.1591705],"study_design_scores_gemma":[0.1030234,0.003181414,0.8879671,0.001612882,0.00018359,0.00006548141,0.0001254305,0.002280816,0.0006657215,0.00004625734,0.0001666043,0.0006813471],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930474,0.002336966,0.00001711935,0.00007885492,0.0007630268,0.002385767,0.00001601721,0.000195566,0.001159319],"genre_scores_gemma":[0.9958797,0.001138406,0.0004886009,0.0006656056,0.0003162377,0.00009697436,0.0001058003,0.0002120992,0.001096557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1584892,"threshold_uncertainty_score":0.9995384,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04643419086277679,"score_gpt":0.3793727557876246,"score_spread":0.3329385649248479,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}